☆ 4.6 Article

Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial

CIRCULATION-HEART FAILURE (2022)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata

Davide Stolfo et al.

Summary: There are disparities in the implementation of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF) across different age groups. Older patients receive less treatment than recommended. Improving strategies and individualized approaches are needed, especially for older patients.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary

Paul A. Heidenreich et al.

Summary: The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure replaces previous guidelines and aims to provide patient-centric recommendations for clinicians based on contemporary evidence, with the goal of improving quality of care and aligning with patients' interests.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction DELIVER Trial

Scott D. Solomon et al.

Summary: This report describes the baseline clinical profiles and management of DELIVER trial participants and how these compare with those in other contemporary heart failure with preserved ejection fraction trials.

JACC-HEART FAILURE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age

Michael Boehm et al.

Summary: This study evaluated the effects of empagliflozin, a glucose-lowering medication, in patients with heart failure and preserved ejection fraction, with a focus on age. The results showed that empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization in patients of all age groups and improved symptoms and quality of life. There were no significant differences in safety between age groups.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

Muthiah Vaduganathan et al.

Summary: This study conducted a meta-analysis of the therapeutic effects of SGLT2 inhibitors in heart failure patients, showing that these drugs can significantly reduce the risk of cardiovascular death and hospitalization for heart failure in heart failure patients, demonstrating their importance in foundational treatment.

LANCET (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

Pardeep S. Jhund et al.

Summary: A patient-level pooled meta-analysis of two trials showed that the sodium-glucose cotransporter 2 inhibitor dapagliflozin can reduce the risk of cardiovascular-associated deaths and hospital admissions for heart failure in patients with heart failure, regardless of ejection fraction.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon et al.

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial

Scott D. Solomon et al.

Summary: The DELIVER trial is an international, multicenter study that aims to evaluate the efficacy and safety of the SGLT2 inhibitor dapagliflozin in patients with heart failure with preserved and mildly reduced ejection fraction. The primary endpoint is time-to-first cardiovascular death or worsening heart failure event, to be assessed in both the full population and in those with specific ejection fraction criteria. DELIVER will provide insights into the role of dapagliflozin as an adjunct therapy in patients with heart failure.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF

Felipe A. Martinez et al.

CIRCULATION (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Election Fraction

Jonathan W. Cunningham et al.

JACC-HEART FAILURE (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials A Systematic Review

Ayman Samman Tahhan et al.

JAMA CARDIOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J. L. Heerspink et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

S. D. Solomon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction

Jasper Tromp et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure

Orly Vardeny et al.

JACC-HEART FAILURE (2019)

Add to Collection

Review Cardiac & Cardiovascular Systems

Arrhythmias in Patients ≥80 Years of Age Pathophysiology, Management, and Outcomes

Anne B. Curtis et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Add to Collection

Review Cardiac & Cardiovascular Systems

Epidemiology of heart failure with preserved ejection fraction

Shannon M. Dunlay et al.

NATURE REVIEWS CARDIOLOGY (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF

Pardeep S. Jhund et al.

EUROPEAN HEART JOURNAL (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Heart Failure With Recovered Ejection Fraction Clinical Description, Biomarkers, and Outcomes

Anupam Basuray et al.

CIRCULATION (2014)

Add to Collection

Review Cardiac & Cardiovascular Systems

Heart failure in elderly patients: distinctive features and unresolved issues

Valentina Lazzarini et al.

EUROPEAN JOURNAL OF HEART FAILURE (2013)

Add to Collection

Article Medicine, General & Internal

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:: the CHARM-Preserved Trial

S Yusuf et al.

LANCET (2003)

Add to Collection

Article Cardiac & Cardiovascular Systems

Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure

CP Green et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.